Mushroom Consumption and Microbiome Alpha Diversity

Mushrooms & Gut Health

52 participants

In a double-blind RCT of 52 adults, daily shiitake beta-glucan supplementation significantly increased Akkermansia muciniphila, a keystone gut bacterium linked to metabolic health and microbiome resilience.

Morales et al., European Journal of Nutrition, 2021

Pilot evidence

lion's mane increased gut alpha diversity and correlated with a brain-gut signal

10 days

button mushroom trial found zero significant microbiome differences

8 weeks

turkey tail RCT produced consistent Bifidobacterium and Lactobacillus shifts

Morales et al., European Journal of Nutrition, 2021

View as image ↗

Alpha diversity has become one of the most searched concepts in gut health: the idea that a richer, more varied microbial community in the gut is associated with better resilience and better health outcomes. The honest question for anyone interested in mushroom consumption microbiome alpha diversity effects is whether consuming mushrooms actually shifts that measurement in humans.

The answer, based on available human data, is: sometimes, under some conditions, for some species, in small and short studies. That qualified answer is more useful than the confident claims circulating in supplement content, and it is what the trial data actually supports.

This article is part of the broader evidence review in Mushrooms as Prebiotics: How They Feed Your Gut Bacteria, specifically covering the alpha diversity question and the human feeding trial data that bears on it.

What Is Alpha Diversity? The Metric at the Center of Mushroom Microbiome Research

Alpha diversity is a measure of the microbial community within a single sample. In gut health research, it quantifies two separate things simultaneously: how many different species of bacteria are present in a person's gut (richness), and how evenly distributed those species are (evenness).

A gut with many different species but with one species dominating all the others has high richness but low evenness. A gut with fewer total species but more balanced distribution between them has lower richness but higher evenness. Alpha diversity scores, like the Shannon diversity index (a mathematical score that summarizes both richness and evenness into one number), capture both dimensions together.

Why does it matter? Higher alpha diversity is associated with better responses to infection, lower rates of metabolic disease, and more resilient gut communities that can recover from disruption. Antibiotic treatment is one of the best-studied causes of sharp alpha diversity loss. Dietary fiber is one of the best-studied causes of sustained alpha diversity gains.

Mushrooms provide a distinctive type of dietary fiber: beta-glucans and chitin, which are long-chain sugar compounds found in mushroom cell walls that human digestive enzymes cannot break down. These compounds reach the colon intact, where they can be fermented by gut bacteria. Whether that fermentation activity results in a measurable increase in alpha diversity in humans is the specific question this article addresses.

The honest answer: the data is thin. One pilot study showed an increase. One crossover RCT showed no effect. Two RCTs showed compositional changes (specific bacteria increasing or decreasing) without reporting alpha diversity as a primary outcome. That is the current state of the human evidence.

What alpha diversity and mushroom consumption data currently shows:

1. Lion's mane (Hericium erinaceus): pilot study showed increased alpha diversity (short-term, small sample, no control group for diversity endpoint)
2. Shiitake beta-glucan (Lentinula edodes): RCT (n=52) showed Akkermansia muciniphila increase, a marker of microbiome quality, without alpha diversity as primary endpoint
3. Button mushroom (Agaricus bisporus): crossover RCT (n=32, 10 days) showed no significant microbiome diversity changes
4. Turkey tail PSP (Trametes versicolor): RCT (n=24, 8 weeks) showed consistent species-level compositional shifts without alpha diversity measurement

The Lion's Mane Pilot: Alpha Diversity Increased, and a Brain-Gut Signal Changed With It

The most direct human evidence for mushrooms and alpha diversity comes from a pilot study published by Xie and colleagues in 2021.^[1] Participants consumed lion's mane (Hericium erinaceus) over a short term, and the researchers measured both gut microbiota composition and a set of serum biochemical markers before and after.

The gut results showed two things happening together: alpha diversity increased, and the relative abundance of bacteria that produce short-chain fatty acids (the molecular byproducts of fiber fermentation that fuel colon cells and lower colonic pH) also increased. Both changes pointed in the direction consistent with prebiotic activity.

The finding that set this study apart from others was a correlation with neuropeptide Y in the blood. Neuropeptide Y is a signaling molecule produced in the nervous system, including in the gut's own nerve cells, that regulates appetite, stress responses, and gut motility. Higher alpha diversity and higher SCFA-producing bacteria were positively correlated with serum neuropeptide Y levels. This suggests a gut-brain signaling connection: the diversity change wasn't isolated to the colon but associated with a neuroactive signal circulating in the blood.

The study's limitations are significant and should be stated directly. It was a pilot study, meaning it was designed to generate hypotheses for larger trials, not to confirm them. Sample size is not published in the available summary data, and the study lacked a control group for the diversity endpoint. The alpha diversity increase is an interesting preliminary signal, not a confirmed clinical finding. For alpha diversity to be considered established, this result would need replication in a randomized, controlled trial. That trial has not been conducted for lion's mane as of 2026.

The connection between lion's mane and intestinal barrier integrity more broadly is covered in Lion's Mane and Leaky Gut: Intestinal Barrier Integrity Research.

The Shiitake RCT: What an Akkermansia Increase Tells Us About Diversity Quality

The strongest human evidence for mushrooms affecting gut microbiome composition, if not alpha diversity specifically, comes from a 2021 double-blind randomized controlled trial by Morales and colleagues.^[2]

Fifty-two adults with mild hypercholesterolemia were randomized to receive 3.5 grams per day of a beta-glucan-enriched extract from shiitake mushrooms (Lentinula edodes), or a placebo, over 12 weeks. At the end of the trial, four specific bacteria had significantly increased in the shiitake group compared to placebo: Akkermansia muciniphila, Ruminococcaceae UCG-014, Erysipelotrichaceae UCG-003, and Subdoligranulum.

The most relevant for gut microbiome quality discussion is Akkermansia muciniphila. This bacterium lives in the mucus layer that coats the inside of the colon and is considered a keystone species, meaning its presence supports the broader health of the gut community around it. Low Akkermansia levels are consistently observed in people with obesity, type 2 diabetes, and metabolic syndrome. Increasing Akkermansia through dietary intervention has become an active research target.

The Morales study did not report alpha diversity metrics as a primary endpoint, so it cannot directly answer whether overall species richness or evenness changed. What it can say is that a specific bacterium strongly associated with healthy, diverse microbiomes increased in response to shiitake beta-glucan supplementation. The compositional shift toward Akkermansia is not the same measurement as alpha diversity, but it reflects a qualitative improvement in microbiome composition.

The shiitake beta-glucan data also connects to the prebiotic mechanism covered in How Beta-Glucans Epigenetically Reprogram Immune Cells; the same fiber driving microbiome changes also has direct effects on immune cell programming.

The Null Result: Ten Days of Button Mushrooms Changed Nothing

One of the most important studies for accurately interpreting the mushroom microbiome literature is one that showed no effect.

Hess and colleagues published a 2018 randomized crossover study of 32 healthy adults.^[3] Participants were assigned to consume either a protein-matched diet emphasizing button mushrooms (Agaricus bisporus) or a protein-matched diet emphasizing meat for 10 days, then crossed over to the other condition after a washout period. The researchers measured SCFA concentrations in stool, breath hydrogen (a marker of fermentation activity), stool frequency, and fecal pH.

The result: no significant differences between conditions on any measured outcome. Not in SCFA output. Not in microbiome diversity markers. Not in stool characteristics.

This null result does not mean mushrooms have no gut effects. It means that 10 days of button mushroom consumption, matched for protein, did not produce detectable SCFA or microbiome changes compared to meat consumption in healthy adults. Several reasons could explain this. Button mushrooms (Agaricus bisporus) contain less beta-glucan per gram than species like turkey tail, lion's mane, or shiitake. Ten days may be too short a duration to shift a gut microbiome that has been established over years. And the comparison was against meat rather than a matched fiber control, which limits what conclusions can be drawn.

The honest takeaway from Hess 2018: species choice and duration both matter. Short-term consumption of lower-beta-glucan species may not move the needle on gut diversity metrics. Studies showing positive effects from turkey tail or shiitake use species with higher beta-glucan concentrations and test durations of 8 to 12 weeks. The same approach applied to button mushrooms for 10 days produced nothing detectable.

For the broader clinical evidence on which mushrooms have the strongest human microbiome data, see Mushroom Consumption and Bacterial Diversity: Clinical Evidence and Which Mushrooms Are the Best Prebiotics? A Species Comparison.

Turkey Tail's 8-Week Shifts: When Compositional Changes Don't Include Alpha Diversity Measurement

The Pallav 2014 randomized clinical trial of turkey tail (Trametes versicolor) polysaccharopeptide (PSP) in 24 healthy adults is the most-cited human evidence for mushrooms affecting gut bacteria composition.^[5]

Over 8 weeks, PSP supplementation consistently increased Bifidobacterium species and Lactobacillus species while decreasing Clostridium species. These are directional changes associated with a healthier microbiome profile. The study's most striking comparison: a parallel arm receiving amoxicillin (a common broad-spectrum antibiotic) showed a lasting disruption (elevated Escherichia/Shigella species) that persisted 42 days after the antibiotic was stopped. Turkey tail PSP produced no comparable disruption.

What Pallav 2014 did not measure is alpha diversity as a primary endpoint. The study used bTEFAP sequencing, an older microbial DNA analysis technology that has largely been replaced by 16S rRNA sequencing in more recent trials. This means the dataset cannot be reanalyzed with modern alpha diversity metrics. The study shows species-level compositional changes but cannot answer whether overall diversity (richness and evenness combined) shifted.

This distinction matters. A microbiome can shift compositionally (with specific bacteria increasing or decreasing) without necessarily changing its overall diversity score. The alpha diversity question and the compositional question are related but different. Turkey tail's 8-week data answers the compositional question well; it leaves the alpha diversity question open.

For a deeper examination of the turkey tail gut evidence specifically, see Turkey Tail and Gut Bacteria: The Most-Studied Prebiotic Mushroom.

What Honest Mushroom Alpha Diversity Research Would Actually Require

A 2021 systematic review of randomized controlled trials on fungal beta-glucans by Vlassopoulou and colleagues provides the highest-level synthesis of the available evidence.^[4] The review covers immune, metabolic, and gut-related outcomes across multiple trials and mushroom species. It confirms that fungal beta-glucans produce measurable effects, but it also flags the limitations that prevent strong conclusions: study heterogeneity in species used, doses, durations, and populations; small sample sizes; and short intervention periods.

The alpha diversity gap in particular is striking. Most published human mushroom microbiome trials have measured specific bacterial species going up or down. They have not been designed with alpha diversity as a primary endpoint, powered for diversity detection, or run long enough to capture the sustained shifts that would be needed to see a diversity change in an already-stable adult gut.

What would rigorous alpha diversity research on mushrooms actually look like? At minimum: a randomized controlled design with an adequate sample size (at minimum n=50 per arm), an intervention of at least 12 weeks, 16S rRNA sequencing or shotgun metagenomics as the analytical method, and alpha diversity (Shannon index or similar) as a pre-specified primary endpoint. It would also need to test specific mushroom species and beta-glucan doses rather than generic "mushroom consumption."

No published trial for any mushroom species meets all of these criteria with alpha diversity as the primary outcome. The lion's mane pilot showed an increase in a small, uncontrolled study. The shiitake RCT showed Akkermansia growth in a well-powered trial but didn't measure diversity directly. The evidence for mushrooms specifically increasing alpha diversity in humans is promising but preliminary.

The broader comparative evidence across species, covering which types of mushroom polysaccharides affect which bacteria in what populations, is covered in How Mushrooms Change Your Gut Microbiome: Research Review and Mushrooms and Firmicutes/Bacteroidetes Ratio: Metabolic Implications.

The Bottom Line

The human trial data on mushrooms and gut microbiome alpha diversity is limited and mixed. A pilot study found that lion's mane consumption increased alpha diversity and correlated with neuropeptide Y levels, but it was small and uncontrolled. A robust shiitake RCT showed Akkermansia growth without directly measuring diversity. A well-designed button mushroom crossover trial found no microbiome effects in 10 days. Turkey tail's 8-week compositional evidence is the strongest in the cluster but did not measure diversity. No published randomized controlled trial for any mushroom species uses alpha diversity as a primary endpoint with adequate sample size and duration. That gap defines the current state of the evidence.

Frequently Asked Questions

What is alpha diversity in the gut microbiome?

Alpha diversity is a measure of bacterial species richness and evenness within a single gut sample. It combines two separate things: how many different bacterial species are present, and how evenly distributed those species are. Higher alpha diversity is associated with a more resilient gut microbiome that recovers better from illness and dietary disruption. The Shannon diversity index is the most commonly reported alpha diversity metric in human gut health research, combining species count and evenness into a single number.

Do mushrooms increase gut microbiome diversity?

The human evidence is limited. A pilot study found that short-term lion's mane consumption increased gut microbiota alpha diversity and SCFA-producing bacteria abundance. A shiitake RCT (n=52) increased Akkermansia muciniphila, a keystone bacterium associated with microbiome health, without measuring alpha diversity directly. A button mushroom crossover trial (n=32, 10 days) found no significant microbiome diversity changes. No large, long-duration randomized controlled trial has tested any mushroom species with alpha diversity as the primary endpoint.

Which mushrooms increase gut bacterial diversity the most?

Based on available human data, lion's mane (Hericium erinaceus) is the only species with direct pilot evidence for alpha diversity increase. Shiitake (Lentinula edodes) has an RCT showing Akkermansia muciniphila growth, a quality marker of microbiome composition. Turkey tail (Trametes versicolor) has the strongest 8-week human evidence for compositional shifts (Bifidobacterium and Lactobacillus increases) but was not measured for diversity. Button mushrooms (Agaricus bisporus) produced no measurable effects in 10 days in healthy adults. Species with higher beta-glucan concentrations and longer study durations consistently produce stronger results.

How do you increase microbiome diversity with diet?

Dietary fiber is the most established dietary driver of gut microbiome diversity. High-fiber diets consistently increase alpha diversity compared to low-fiber diets in controlled studies. Mushrooms provide a distinctive type of dietary fiber (beta-glucans and chitin) that resists human digestion and reaches the colon intact for bacterial fermentation. Whether mushroom-specific beta-glucan intake produces diversity gains comparable to plant fiber intake in humans has not been established in large controlled trials, though the pilot evidence for lion's mane and the shiitake compositional data are consistent with a prebiotic mechanism.

Does lion's mane mushroom improve gut microbiome diversity?

A 2021 pilot study found that short-term lion's mane consumption was associated with increased gut microbiota alpha diversity and increased abundance of SCFA-producing bacteria. The diversity changes correlated positively with serum neuropeptide Y levels, suggesting a gut-brain signaling connection. These results are preliminary: the study was a pilot without a matched control group for the diversity endpoint, and sample size details were limited. A randomized controlled trial powered to detect alpha diversity changes from lion's mane consumption has not been published.

Sources & References

1. 1RTHM-01458·Xie, Xiao-Qian et al. (2021). “Influence of Short-Term Consumption of Hericium erinaceus on Serum Biochemical Markers and the Changes of the Gut Microbiota: A Pilot Study..” Nutrients.Study breakdown →PubMed →↩
2. 2RTHM-01408·Morales, Diego et al. (2021). “Modulation of human intestinal microbiota in a clinical trial by consumption of a β-D-glucan-enriched extract obtained from Lentinula edodes..” European journal of nutrition.Study breakdown →PubMed →↩
3. 3RTHM-00963·Hess, Julie et al. (2018). “Impact of Agaricus bisporus Mushroom Consumption on Gut Health Markers in Healthy Adults..” Nutrients.Study breakdown →PubMed →↩
4. 4RTHM-01451·Vlassopoulou, Marigoula et al. (2021). “Effects of fungal beta-glucans on health - a systematic review of randomized controlled trials..” Food & function.Study breakdown →PubMed →↩
5. 5RTHM-00630·Pallav, Kumar et al. (2014). “Effects of polysaccharopeptide from Trametes versicolor and amoxicillin on the gut microbiome of healthy volunteers: a randomized clinical trial..” Gut microbes.Study breakdown →PubMed →↩